1052087-90-7

1052087-90-7 structure

Name: PSB 0739
Chemical Name: Disodium 1-amino-4-[(4-anilino-3-sulfonatophenyl)amino]-9,10-diox o-9,10-dihydro-2-anthracenesulfonate
CAS Number: 1052087-90-7
Molecular Formula: C₂₆H₁₇N₃Na₂O₈S₂
Molecular Weight: 609.54
Catalog: Signaling Pathways GPCR/G Protein P2Y Receptor
Create Date: 2016-11-27 07:45:21
Modify Date: 2024-01-28 15:56:48
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect[1].

Name	Disodium 1-amino-4-[(4-anilino-3-sulfonatophenyl)amino]-9,10-diox o-9,10-dihydro-2-anthracenesulfonate

Description	PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> P2Y Receptor
In Vitro	PSB-0739 is a potent competitive non-nucleotide antagonist at the human P2Y12 receptor with a pA2 value of 9.8[2]. PSB-0739 inhibits ADP-evoked Ca2+ responses with an EC50 of 5.4±1.8 μM and causes a rightward parallel shift in the ADP concentration–response curve in THP-1 cells[3]. Cell Viability Assay[3] Cell Line: THP-1 monocytic cell line Concentration: 10 nM, 100 nM, 1 μM, 10 μM Incubation Time: Result: Attenuated ADP-evoked responses (IC50=5.4±1.8 μM).
In Vivo	PSB-0739 (0.01-0.3 mg/kg, intrathecally) has dose-dependent and significant antihyperalgesic effect in low doses. The minimal effective dose (mED) is 0.1 mg/kg[4]. Animal Model: Male Wistar rats, 150-250 g, 6-8/group[4] Dosage: 0.01, 0.03, 0.1, 0.3 mg/kg Administration: Intrathecal injection ( i.t.) Result: Displayed a dose-dependent inhibitory effect on mechanical hyperalgesia in the range of 0.01–0.1 mg/kg.
References	[1]. Younis Baqi, et al. High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y₁₂ receptors. J Med Chem. 2009 Jun 25;52(12):3784-93. [2]. Kristina Hoffmann, et al. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y₁₂ receptor. J Pharmacol Exp Ther. 2009 Nov;331(2):648-55. [3]. J J Micklewright,et al. P2Y 12 receptor modulation of ADP-evoked intracellular Ca²⁺ signalling in THP-1 human monocytic cells. Br J Pharmacol.2018 Jun;175(12):2483-2491. [4]. Gergely Horváth, et al. Central P2Y₁₂ receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis. 2014 Oct;70(100):162-78.

Molecular Formula	C₂₆H₁₇N₃Na₂O₈S₂
Molecular Weight	609.54
Exact Mass	609.02500
PSA	215.38000
LogP	6.22840

1052087-90-7	1052089-16-3
72255-76-6	1802226-88-5
1627710-30-8	1802226-87-4
1092351-10-4	409344-71-4
1399049-81-0	2332835-02-4
2228522-68-5	1158522-08-7
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	2137569-22-1